BioPharm International, June 2012 Issue (PDF)
Celebrating 25 Years of BioPharma Innovation
Back-to-Basics with PDUFA V
BIO is calling for a more patient-centric approach to user-fee reauthorization.
Determining Process Quality Metrics for CMOs
Implementing quality by design makes the determination of quality metrics across CMOs and sponsors essential.
New Biopharmaceuticals
A review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011.
Reducing Human Error
Leading industry collaborators outline top 10 best practices for human error reduction.
Interview with FDA: Adopting New Strategies to Oversee Global Economy
In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.
Know the Regulations
The contract provider needs to know as much as the NDA holder.
Creating a Product Portfolio from the Ground Up
Mike Clayman, CEO of Flexion Therapeutics, talks about his company's strategy to focus on a single therapeutic area.
25 Years of Nanoparticles: A Look Forward
Panayiotis P. Constantinides of Biopharmaceutical & Drug Delivery Consulting on growth of nanoparticle delivery systems.
25 Years of BioPharma Industry Growth
A review of key industry shifts and promises for the future.
Developing Alternatives to ELISA-Based Biomarker Assays
The authors discuss a new, rapid immunoassay for the detection of biomarkers.
25 Years of Protein Expression
Charles H. Squires of Pfenex discusses advances in expression platform solutions.
Developing Discoveries into New Therapeutics
Formulators and developers are at the heart of the industry's basic premise-they are saving lives.
25 Years of Biopharmaceutical Innovation: An Expert Roundtable
Industry experts discuss significant achievements. Plus: What's in store for the future.
BioPharm Celebrates 25 Years
In this online extra, Board Members comment on major industry changes over the past few decades.
